Justification for the use of HRT in the long-term prevention of osteoporosis

Maturitas

Volumn 51, Issue 2, 2005, Pages 113-126

  Stevenson, John C ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Hormone replacement therapy; Osteoporosis; Postmenopausal

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; DYDROGESTERONE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; HORMONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; PLACEBO; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

ACUTE HEART INFARCTION; ALZHEIMER DISEASE; BONE DENSITY; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; COLORECTAL CARCINOMA; CORONARY ARTERY DISEASE; DEMENTIA; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FRAGILITY FRACTURE; HEART DISEASE; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; MENOPAUSAL SYNDROME; META ANALYSIS; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; PREVENTIVE MEDICINE; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; STROKE; THROMBOGENESIS; VENOUS THROMBOEMBOLISM;

BONE DENSITY; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COGNITION; COLORECTAL NEOPLASMS; DEMENTIA; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, BONE; HUMANS; META-ANALYSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; POSTMENOPAUSE; QUALITY OF LIFE; RISK FACTORS; TREATMENT OUTCOME;

EID: 19444384640     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2005.01.012     Document Type: Review

References (71)

1. L.J. Melton, E.J. Atkinson, W.M. O'Fallon, H.W. Wahner, and B.L. Riggs Long-term fracture risk prediction with bone mineral measurements made at various skeletal sites J Bone Miner Res 8 1993 1227 1233
2. D. Marshall, O. Johnell, and H. Wedel Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures BMJ 312 1996 1254 1259
3. A.M. Schott, C. Cormier, and D. Hans How hip and whole body bone mineral density predict hip fracture in elderly women. The EPIDOS prospective study Osteoporos Int 8 1998 247 254
4. K.G. Faulkner Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 15 2000 183 187
5. P. Hadji, T. Rabe, and O. Ortmann The possible role of estrogens and progestagens in the prevention of osteoporosis Geburtsh Frauenheilk 62 2002 436 445
6. M.C. Hochberg, S. Greenspan, R.D. Wasnuch, P. Miller, D.E. Thompson, and P.D. Ross Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents J Clin Endocrinol Metab 87 2002 1586 1592
7. B. Ettinger, A. Pressman, P. Sklarin, D.C. Bauer, J.A. Cauley, and S.R. Cummings Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures J Clin Endocrinol Metab 83 1998 2239 2243
8. T. Yasui, H. Uemura, and M. Tezuka Biological effects of HRT in relation to serum estradiol levels Horm Res 56 2001 38 44
9. S.R. Cummings, W.S. Browner, and D. Bauer Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research groups N Engl J Med 339 1998 733 738
10. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, 1994.
11. The Writing Group for the PEPI Effects of hormone therapy on bone mineral density - results from the postmenopausal estrogen/progestin interventions (PEPI) trial JAMA 276 1996 1389 1396
12. R. Lindsay, J.C. Gallagher, M. Kleerekoper, and J.H. Pickar Effect of lower doses of conjugated estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women JAMA 287 2002 2668 2676
13. B. Lees, and J.C. Stevenson The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17β and dydrogesterone Osteoporos Int 12 2001 251 258
14. J.C. Stevenson, P. Teter, and B. Lees 17β-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women Maturitas 38 2001 197 203
15. G.A. Greendale, M. Espeland, S. Sloane, R. Marcus, and E. Barrett-Connor PEPI Safety Follow-Up Study (PSFS) Investigators. Bone mass response to discontinuation of long-term hormone replacement therapy. Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) safety follow-up study Arch Intern Med 162 2002 665 672
16. P. Eiken, N. Kolthoff, and S. Pors Nielsen Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women Bone 19 1996 191S 193S
17. T. Naessén, I. Oersson, H.-O. Adami, R. Bergstrom, and L. Bergkvist Hormone replacement therapy and the risk for first hip fracture Ann Intern Med 113 1990 95 103
18. J.A. Cauley, D.G. Seeley, K. Ensrud, B. Ettinger, D. Black, and S.R. Cummings Estrogen replacement therapy and fractures in older women Ann Intern Med 122 1995 9 16
19. K. Michaëlsson, J.A. Baron, and Y. Farahmand Hormone replacement therapy and risk of hip fracture: population based case-control study BMJ 316 1998 1858 1863
20. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women JAMA 288 2002 321 333
21. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. J Am Med Assoc 2004;291:1701-12.
22. M.H. Komulainen, H. Kröger, and M.T. Tuppurainen HRT and Vitamin D in prevention of non-vertebral fractures in postmenopausal women; a 5-year randomized trial Maturitas 31 1998 45 54
23. L. Mosekilde, H. Beck-Nielsen, and O.H. Sørensen Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study Maturitas 42 Suppl 1 2002 S59 S71
24. K. Michaëlsson, J.A. Baron, O. Johnell, I. Persson, and S. Ljunghall Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture Osteoporos Int 8 1998 540 546
25. G. Wells, P. Tugwell, and B. Shea V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women End Rev 23 2002 529 539
26. D.J. Torgerson, and S.E.M. Bell-Syer Hormone replacement therapy and prevention of nonvertebral fractures. A meta-analysis of randomized trials JAMA 285 2001 2891 2897
27. D.J. Torgerson, and S.E.M. Bell-Syer Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials BMC Musculoskelet Disord 2 2001 7
28. C. Le Pen, F. Maurel, and G. Breart The long-term effectiveness of preventive strategies for osteoporosis in postmenopausal women: a modeling approach Osteoporos Int 11 2000 524 532
29. J. Magaziner, E.M. Simonsick, T.M. Kashner, J.R. Hebel, and J.E. Kenzora Survival experience of aged hip fracture patients Am J Public Health 79 1989 274 278
30. D.M. Kado, W.S. Browner, L. Palermo, M.C. Nevitt, H.K. Genant, and S.R. Cummings Vertebral fractures and mortality in older women. A prospective study Arch Intern Med 159 1999 1215 1220
31. D. Hosking, C.E.D. Chilvers, and C. Christiansen Prevention of bone loss with alendronate in postmenopausal women under 60 years of age N Engl J Med 338 1998 485 492
32. K.M. Prestwood, M. Gunness, D.B. Muchmore, Y. Lu, M. Wong, and L.G. Raisz A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women J Clin Endocrinol Metab 85 2000 2197 2202
33. K.S. Tsai, M.L. Yen, and H.A. Pan Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women Osteoporos Int 12 2001 1020 1025
34. P. Ravn, M. Bidstrup, and R.D. Wasnich Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial Ann Intern Med 131 1999 935 942
35. B. Ettinger, D.M. Black, and B.H. Mitlak Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 1999 637 645
36. S.K. Sankaran Osteoporosis prevention and treatment. Pharmacological management and treatment implications Drugs Aging 9 1996 472 477
37. B.P. Towler, L. Irwig, P. Glasiou, D. Weller, and J. Kewenter Screening for colorectal cancer using the faecal occult blood test, hemoccult Cochrane Database Syst Rev 2 2000 CD001216
38. F. Grodstein, P.A. Newcomb, and M.J. Stampfer Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis Am J Med 106 1999 574 582
39. K. Nanda, L.A. Bastian, V. Hasselblad, and D.L. Simel Hormone replacement therapy and the risk of colorectal cancer: a meta- analysis Obstet Gynecol 93 1999 880 888
40. C. Behl Neuroprotective strategies in Alzheimer's disease Adv Exp Med Biol 513 2002 475 496
41. V.W. Henderson, A. Paganini Hill, C.K. Emanuel, M.E. Dunn, and J.G. Buckwalter Estrogen replacement therapy in older women Arch Neurol 51 1994 896 900
42. M.X. Tang, D. Jacobs, and Y. Stern Effect of estrogen during menopause on risk and age of onset of Alzheimer's disease Lancet 348 1996 429 432
43. P.P. Zandi, M.C. Carlson, and B.L. Plassman Hormone replacement therapy and incidence of Alzheimer disease in older women. The Cache county study JAMA 288 2002 2123 2129
44. E.S. LeBlane, J. Janowsky, B.K.S. Chan, and H.D. Nelson Hormone replacement therapy and cognition. Systematic review and meta-analysis JAMA 285 2001 1489 1499
45. R.E. Slavin Best practice synthesis: an alternative to meta-analytic and traditional reviews Educ Res 15 1986 5 11
46. S.R. Rapp, M.A. Espeland, and S.A. Shumaker Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial JAMA 289 2003 2663 2672
47. A. Shumaker, C. Legault, and R. Rapp Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study JAMA 289 2003 2651 2662
48. B.B. Sherwin, and T. Tulandi 'Add-back' estrogen reverses cognitive deficits induced by a gonadotropin releasing-hormone agonist in women with leiomyomata uteri J Clin Endocrinol Metab 81 1996 2545 2549
49. A.N.A. Tosteson, S.E. Gabriel, and T.S. Kneeland Has the impact of hormone replacement therapy on health-related quality of life been undervalued? J Womens Health Gend Based Med 9 2000 119 130
50. J. Hays, J.K. Ockene, and R.L. Brunner Effects of Estrogen plus Progestin on Health-Related Quality of life N Engl J Med 348 2003 1839 1854
51. S. Hulley, D. Grady, and T. Bush Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Eestrogen/progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 613
52. M. Neves-e-Castro, G. Samsioe, M. Dören, and S.O. Skouby Results from the WHI and HERS II - implications for women and the prescriber of HRT Maturitas 42 2002 255 258
53. H.P.G. Schneider The view of The International Menopause Society on the Women's Health Initiative Climacteric 5 2002 211 216
54. T.S. Mikkola, and T.B. Clarkson Estrogen replacement therapy, atherosclerosis and vascular function Cardiovasc Res 53 2002 605 619
55. F. Grodstein, J.E. Manson, G.A. Colditz, W.C. Willett, F.E. Speizer, and M.J. Stampfer A prospective, observational study of postmenopausal hormone replacement therapy and primary prevention of cardiovascular disease Ann Intern Med 133 2000 933 941
56. D.M. Herrington, D.M. Reboussin, and K.B. Brosnihan Effects of estrogen replacement on the progression of coronary artery atherosclerosis N Engl J Med 343 2000 522 529
57. M.R. Adams, T.C. Register, D.L. Golden, J.D. Wagner, and J.K. Williams Medroxyprogesterone acetate antagonizes inhibitora effects of conjugated equine etsrogens on coronary artery atherosklerosis Arterioscler Thromb Vasc Biol 17 1997 217 221
58. J.K. Williams, E.K. Honore, S.A. Washburn, and T.B. Clarkson Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys J Am Coll Cardiol 24 1994 1757 1761
59. A.D. Pradhan, J.E. Manson, and J.E. Rossouw Inflammatory biomarkers, hormone replacement therapy and incident coronary heart disease JAMA 288 2002 980 987
60. D.M. Herrington, E. Vittinghoff, and F. Lin Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement Study Circulation 105 2002 2962 2967
61. D. Grady Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II) JAMA 288 2002 49 57
62. J.C. Stevenson Hormone replacement therapy and coronary heart disease Pract Cardiovasc Risk Man 1 2003 7 11
63. Hormone replacement therapy in the post-Women's Health Inititive era. A Report of a meeting held in Funchal, Madeira, February 24-25, 2003. Climacteric 2003;6:25.
64. P.Y. Scarabin, E. Oger, and G. Plu-Bureau Estrogen and Thromboembolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk Lancet 362 2003 428 432
65. Million Women Study Collaborators Breast cancer and hormone replacement therapy in the Million Women Study Lancet 362 2003 419 427
66. B. de Lignières, F. de Vathaire, and S. Fournier Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women Climacteric 5 2002 332 340
67. Collaborative Group on Hormone Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer Lancet 350 1997 1047 1059
68. J. Cheek, J. Lacy, S. Toth-Fejel, K. Morris, K. Calhoun, and R.F. Pommier The impact of hormone replacement therapy on the detection and stage of breast cancer Arch Surg 137 2002 1015 1021
69. J.C. Stevenson Long-term effects of HRT Lancet 361 2003 253 254
70. J.P. Zubialde, F. Lawler, and N. Clemenson Estimated gains in life expectancy with use of postmenopausal estrogen therapy: a decision analysis J Fam Pract 36 1993 271 280
71. S. Panico, R. Galasso, and E. Celentano Large-scale hormone replacement therapy and life expectancy: results from an international comparison among European and North American populations Am J Public Health 90 2000 1397 1402